HLA-A and neoplasm: HLA-A and HLA-B belong to MHC class I antigens, and former research have shown that abnormal MHC-I expression and function regulation may be hijacked by tumor cells to evade immune surveillance, thereby promoting tumor progression and impairing the efficacy of cancer immunotherapy (45–47).